Osimertinib Not Yet Recruiting Phase 1 Trials for Lung Cancers Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03891615Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer